Known targets — ChEMBL curated mechanism
CSF1RFGFR1FGFR3FLT1FLT4ITKKDRKITLCKPDGFRAPDGFRB
The experimentally established mechanism targets of Pazopanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 15/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 10/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 9/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazopanib SCHEMBL29392503 | 1.00 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL159487 | 0.99 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29520402 | 0.99 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29386934 | 0.99 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL935692 | 0.98 | KDR (0.97) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL3173301 | 0.97 | KDR (0.95) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025440 | 0.95 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025438 | 0.95 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025441 | 0.94 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 | |
| SCHEMBL22720091 | 0.94 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17280 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | claimed |
| WO-2011150044-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | claimed |
| JP-2011528326-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2364163-A1 | COMPOSITION COMPRISING IN VITRO EXPANDED T-LYMPHOCYTES AND VESSEL FORMATION INHIBITORS SUITABLE IN THE TREATMENT OF CANCER | SentoClone International AB (SE) | 2011-09-14 | — | — | EP | claimed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010006808-A1 | COMPOSITION COMPRISING IN VITRO EXPANDED T-LYMPHOCYTES AND VESSEL FORMATION INHIBITORS SUITABLE IN THE TREATMENT OF CANCER | SENTOCLONE AB (SE) | 2010-01-21 | — | — | WO | claimed |
| US-20100015161-A1 | Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer | SENTOCLONE AB (SE) | 2010-01-21 | — | — | US | claimed |
| EP-1343782-B1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | claimed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |